Abcellera Biologics INC. (ABCL) — 10-Q Filings

10-Q Filings (6)

• AbCellera's Q3 Loss Widens Amid Revenue Growth, Cash Burn Continues — Nov 6, 2025 Risk: high
  AbCellera Biologics Inc. (ABCL) reported a net loss of $57.1 million for the three months ended September 30, 2025, an increase from a net loss of $51.1 million
• AbCellera Revenue Plummets 69% Amid Program Slowdown — Aug 7, 2025 Risk: high
  AbCellera Biologics Inc. reported a significant decrease in total revenue for Q2 2025, falling to $15.2 million from $48.7 million in Q2 2024, a 68.8% decline.
• AbCellera Biologics Files Q1 2025 10-Q — May 8, 2025 Risk: low
  AbCellera Biologics Inc. filed its Q1 2025 10-Q report on May 8, 2025, for the period ending March 31, 2025. The company, based in Vancouver, Canada, operates i
• AbCellera Biologics Files Q3 2024 10-Q — Nov 4, 2024 Risk: medium
  AbCellera Biologics Inc. filed its 10-Q for the period ending September 30, 2024. The company reported financial results for the third quarter and the first nin
• AbCellera Biologics Inc. Files Q2 2024 10-Q Report — Aug 6, 2024 Risk: low
  AbCellera Biologics Inc. filed its quarterly report for the period ended June 30, 2024. The company, registered with the SEC under file number 001-39781, trades
• AbCellera Biologics Files 10-Q for Period Ending March 31, 2024 — May 7, 2024 Risk: medium
  AbCellera Biologics Inc. (ABCL) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Revenue for the three months ended March 31, 2024, was $22.5 millio

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX